Retaglutide and tirzepatide are newer GLP-1 receptor agonists gaining attention as effective treatment options for type 2 diabetes. These medications promote insulin secretion from the pancreas, reduce glucagon release, and slow down gastric emptying, leading to improved glycemic control. Retaglutide is administered intravenously, while tirzepatide